業務策略
實踐既定戰略,創造最大價值

業務模式

我們的目標是促進範圍廣泛的早期階段創新治療及診斷方案的研發和改進。最終通過再授權及商品化各項臨床成果,創造價值和收入,從而進一步擴充我們的正發展項目之組合和促進業務的可持續增長。

 

業務策略

多元醫療領域發展

我們正研發適用於不同疾病/治療的藥品及儀器候選產品。我們相信,通過分散研究資源,能有夜提高我們任何一個旗下項目進入臨床研究階段的成功機會,並因此提升我們的企業價值。截至2017年12月31日,我們在腦神經、傳染病、胃腸病、腫瘤、手術機器人和自然健康等領域取得11項專利技術的授權。

嚴格篩選具潛力產品,
有效擴充研發項目組合

我們嚴格挑選具卓越科學素質的創新產品作為研發對象,並會審視它們的市場潛力和需求規模,例如該產品能否滿足目前未被滿足的醫療需求。為此,知臨集團旗下的Aptorum Therapeutics Limited 成立了科技評估委員會,幫助我們評估篩選項目和為未來的收購或爭取獲得專利授權的對象提供科學觀點。我們將繼續尋找適用於罕見疾病(例如:罕見的癌症)和未被滿足之醫療需求的研發對象,並確保它們有強大的臨床前及早期臨床研究數據和商業價值。

與頂尖學術機構和委託研究機構合作

我們相信,通過與頂尖學術機構和委託研究機構合作,是我們在建立和擴充產品組合的高成本效益的重要戰略。我們與全球多間頂尖學術機構建立了良好關係,並會繼續強化我們之間的合作,例如以贊助形式,向大學主要研究人員提供資源,在與我們項目公司相關的專業範疇進行深入研究,我們則能擁有獲得獨家專利的優先權。另外,我們也與藥廠簽訂協議,以委託研究機構的形式,協助我們推行研究項目的進程。

擴充自家製藥開發中心

我們相信,由APD負責營運的研發中心與其他項目公司的科學家之間的緊密合作,能提升研發項目的臨床發展和商業潛力。另外,APD將尋求外部製藥公司或委託研究機構進行部分臨床前或臨床階段的發展,以協助旗下項目公司的研發進程。

借力管理層的專業知識、
經驗和商業網絡

管理層的專業知識和經驗,加上他們豐富的學術和商業網絡資源,將帶領知臨集團成為推動醫療創新邁向臨床研究和在全球主要市場推出上市的理想平台。知臨集團的管理層團隊擁有豐富的環球經驗,在醫療行政和在醫藥產品的開發、併購、發展、註冊及全球上市等方面均有豐厚成就;。我們也會利用管理層在銀行業和金融業的經驗,強化自身的運營能力,為旗下項目打造最高效的財務方案。

策略性立足香港,
貫通龐大中國市場

中國是全球第二大的保健市場,我們計劃將旗下產品在中國市場行銷,是我們的增長策略的重要一環。2017年10月,中國政府宣佈將接受境外臨床試驗數據以加速內地新藥的審批程序,為海外製藥公司帶來龐大的潛在增長動力。我們相信,香港作為中國的特別行政區,立足此地將賦予我們獲取中國食品藥品監督管理局(“CFDA”)認證和進入全球第二大醫療保健市場的獨特優勢。我們的重要合作伙伴,香港大學和香港中文大學均已成為CFDA認證的藥物臨床試驗中心。

利用政府資源,推動項目發展

香港政府j密切注視本地生命科技行業發展,並提供多項支持和資助。我們將主動尋求政府的支持,以推進旗下研究項目的基礎和發展。

×
使用條款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.